

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | — | — | — | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | — | 1 |
| Drug common name | SODELGLITAZAR |
| INN | sodelglitazar |
| Description | Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.
|
| Classification | Small molecule |
| Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (not thiazolidene derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3F)nc2C)ccc1OC(C)(C)C(=O)O |
| PDB | — |
| CAS-ID | 447406-78-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2104984 |
| ChEBI ID | — |
| PubChem CID | 9805950 |
| DrugBank | — |
| UNII ID | 6G973E04VI (ChemIDplus, GSRS) |
